In this month's Round Up areas highlighted include the synergistic action of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes in the reduction of cardiovascular risk, aspirin and breast cancer, and exercise and inflammatory bowel disease (IBD).